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Background: Pygopus 2 (Pygo2) is a Pygo family member and an important component of the Wnt signaling
transcriptional complex. Despite this data, no clinical studies investigating Pygo2 expression in lung cancer have yet
been reported.
Methods: In the present study, the expression patterns of Pygo2 were evaluated by immunochemistry in 168
patients with non-small cell lung cancer (NSCLC). We used small interfering RNA (siRNA) to specifically silence
Pygo2, and investigated its effect on cell growth by an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay and flow cytometry analysis in human lung cancer cell lines.
Results: Immunohistochemical analysis showed low expression of Pygo2 in normal lung tissues and increased
nuclear expression in lung cancer tissues, either with or without perinuclear expression. Abnormal Pygo2 expression
was associated with poor differentiation and a high Tumor (T), Node (N) and Metastases (M) stage in NSCLC
patients, and correlated with poor prognosis. Using MTT assay we observed that Pygo2 downregulation inhibited
cell proliferation; in addition, flow cytometry analysis showed that Pygo2 knockdown induced apoptosis and
increased numbers of G1-phase cells and a reduction in S-phase cells.
Conclusions: We therefore conclude that abnormal Pygo2 protein expression may be a marker for advanced
NSCLC. Furthermore, Pygo2 knockdown suppresses cell growth.
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Pygopus proteins are critical elements of the canonical
Wnt/β-catenin transcriptional complex which is essen-
tial for activation of Wnt target genes [1-4]. In humans,
there are two Pygo genes, Pygo1 and Pygo2 [1,5]. Pygo2
has been implicated in Wnt-independent roles in both
cancer [6] and development [7,8]. Due to the diverse
roles of Pygo2 in cell regulation, disruption of Pygo2
function has been proposed as a strategy for targeting
malignant cells [2,9]. In support of this hypothesis, stud-
ies have demonstrated that increased Pygo2 expression
is specifically required for proliferation of breast and* Correspondence: wangeh@hotmail.com
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reproduction in any medium, provided the orepithelial ovarian cancer cells. Furthermore, silencing of
endogenous Pygo2 suppresses the growth of breast and
epithelial ovarian cell lines [2,6,10]. Increased expression
of nuclear Pygo2 has been reported in 82% of epithelial
ovarian cancer tissue samples, compared with tissues
from the early stages of the disease [11]. These observa-
tions strongly suggest that Pygo2 has an important role
in the development of these cancers, although it remains
unknown whether Pygo2 has a general role in mamma-
lian cancer development [12-14], and in particular
whether Pygo2 is overexpressed in lung cancer tissues.
To address this question, we examined Pygo2 expression
patterns and their prognostic significance in patients
with non-small cell lung carcinoma (NSCLC). Pygo2
protein levels were compared in lung cancer tissues and
corresponding normal lung tissues, as well as in A549,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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more, we knocked down Pygo2 with small interfering
RNA (siRNA) in human lung cancer cell lines and inves-
tigated its effect on cell proliferation.
Methods
Patients and specimens
This study was conducted with the approval of the local
institutional review board at the China Medical Univer-
sity. Primary tumor specimens were obtained from 168
patients (107 males and 61 females) diagnosed with lung
squamous cell carcinoma (SCC) or adenocarcinoma who
underwent complete resection at the First Affiliated
Hospital of China Medical University between 2002 and
2004. Follow-up information was obtained from a review
of the patients’ medical records. None of the patients
had received radiotherapy or chemotherapy before surgi-
cal resection and all patients were treated with routine
chemotherapy after the operation. The mean age of the
patients was 60 years (range, 31–87 years). Histological
diagnosis and tumor differentiation were determined
using hematoxylin and eosin stained tumor tissue sec-
tions, according to the World Health Organization
(WHO) classification guidelines (2004) [15]. All 168
specimens were re-evaluated with respect to histological
subtype, differentiation and tumor stage. Seventy-two
cases were classified as SCC and 96 as adenocarcinoma
(66 well differentiated, 80 moderately differentiated, and
22 poorly differentiated). Lymph node metastases were
identified in 74 of the 168 patients. The TNM (Tumor,
Node, Metastasis) staging system of the International
Union Against Cancer [16] was used to classify speci-
mens as stage I (n = 56), II (n = 39), or III (n = 73). Of
these samples, 30 fresh specimens, including both the
tumor tissues and corresponding normal tissues, were
also stored at −70°C immediately after resection for pro-
tein extraction.
Cell lines
The immortal human bronchial epithelial cell line, HBE,
and the human lung cancer cell lines A549, PG-BE1,
NCI-H460, LTEP-a-2 and SPC-A-1 were cultured in ei-
ther DMEM or RPMI 1640 medium (both from
Invitrogen, Carlsbad, CA, USA) supplemented with 10%
fetal calf serum (Invitrogen), 100 IU/ml penicillin (Sigma,
St. Louis, MO, USA) and 100 μg/ml streptomycin (Sigma).
Cells were grown on sterile culture dishes and passaged
every 2 days, using 0.25% trypsin (Invitrogen).
The A549 and NCI-H460 cell lines were obtained
from the American Type Culture Collection (Manassas,
VA, USA). PG-BE1 was kindly gifted by Professor Jie
Zheng of Peking University, China. HBE, SPC-A-1 and
LTEP-a-2 were obtained from Shanghai Cell Bank
(Shanghai, China).Immunohistochemistry
Surgically excised tumor specimens were fixed in 10%
neutral formalin, embedded in paraffin and then 4-μm-
thick sections were prepared. Normal bronchial epithe-
lium present in the tumor tissue samples was used as an
internal positive control. Immunostaining was performed
using the avidin–biotin–peroxidase complex method
(UltrasensitiveTM, MaiXin, Fuzhou, China). Sections
were deparaffinized in xylene, rehydrated with graded
alcohols, and then autoclaved in 10 μM citrate buffer
(pH 6.0) for 2 min. Hydrogen peroxide (0.3% v/v) was
applied to block endogenous peroxide activity and
sections were incubated with normal goat serum to re-
duce non-specific antibody binding. Tissue sections were
incubated with Pygo2 rabbit monoclonal primary anti-
bodies (1:200 dilution; EPR2024 [2], Abcam, Cambridge,
MA, USA). Rabbit immunoglobulin (also at a 1:200 di-
lution) was used as a negative control. Antibody stain-
ing was performed at 4°C overnight. Biotinylated goat
anti-rabbit serum immunoglobulin G (IgG) was used as
a secondary antibody. After washing, sections were incu-
bated with streptavidin–biotin-conjugated horseradish
peroxidase and developed with 3,3′-diaminobenzidine
tetrahydrochloride. Counterstaining with hematoxylin was
performed and sections were dehydrated in ethanol before
mounting. Two investigators independently examined all
tumor slides in a randomized manner. Five fields were
examined per slide and 100 cells per field were observed
at 400× magnification. Evaluation of Pygo2 staining in
tissue sections was performed according to the immu-
nohistochemical assessment used by Popadiuk et al. for
epithelial ovarian cancer with minor changes [6]. Briefly,
the Pygo2 staining intensity was scored as − (no signal),
+ (weak), ++ (moderate), +++ (strong); (−) to (+) scores
were considered to be negative (normal Pygo2 expression)
and (++) to (+++) scores were considered to be positive
(abnormal Pygo2 expression).
Western blot analysis
Protein was extracted from tissue samples and cell lines
using the Nuclear Protein and Cell Plasma Protein
Extraction kit (P0028, Beyotime, Shanghai, China) and
protein concentrations were determined with Coomassie
brilliant blue (Sigma), using bovine serum albumin
(BSA) (Invitrogen) as the standard. Protein samples
(50 μg) were separated by 8% or 12% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE)
and transferred to polyvinylidene fluoride membrane
(Millipore, Billerica, MA, USA). After blocking with 1%
BSA in Tris-buffered saline (TBS; 20 mM Tris–HCl,
500 mM NaCl) containing 0.05% Tween-20, the mem-
branes were incubated with rabbit anti-Pygo2 monoclo-
nal antibody (1:5000; Abcam) at 4°C overnight. After
incubation with horseradish peroxidase-coupled anti-
Figure 1 (See legend on next page.)
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Figure 1 Pygo2 expression analysis in lung cancer tissues. Pygo2 staining was classified as negative, weak (light staining; <70% nuclei
stained), moderate (intermediate intensity staining; 80% nuclei stained), or strong (intense staining; >90% nuclei stained). Weak or negative Pygo2
staining was detected in the nuclei of normal bronchial epithelium (A, B). Weak (+) to strong (+++) nuclear accumulation of Pygo2 protein was
observed in lung squamous cell carcinoma (C-H) and adenocarcinoma (I-N). Bar, 50 μm.
Table 1 Pygo2 expression correlates with specific
clinicopathological factors of lung cancer
Clinicopathological factors n Abnormal expression P value
Age
≤ 60 years 71 50 (70.42%) 0.638
> 60 years 97 65 (67.01%)
Gender
Male 107 76 (71.03%) 0.341
Female 61 39 (63.93%)
Histology
SCC 72 49 (68.06%) 0.924
Adenocarcinoma 96 66 (68.75%)
Differentiation
Well 66 38 (57.58%) 0.015
Moderate–poor 102 77 (75.49%)
TNM stage
I–II 95 58 (61.05%) 0.019
III 73 57 (78.08%)
Lymphatic metastasis
No 94 59 (62.77%) 0.074
Yes 74 56 (75.68%)
SCC squamous cell carcinoma, TNM Tumor, Node, Metastasis.
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bands were visualized using ECL Western Blotting
Substrate (Pierce, Rockford, IL, USA) and the BioImaging
Systems (UVP Inc., Upland, CA, USA). Protein levels were
normalized to β-actin proteins.
RNA extraction and reverse transcription polymerase
chain reaction
Total RNA was extracted from cells using TRIzol Reagent
(Invitrogen). Reverse transcription polymerase chain reac-
tion (RT-PCR) was performed using the RNA PCR Kit
(AMV) Version 3.0 (TaKaRa Bio Inc., Dalian, Liaoning,






After 1.5% agarose gel electrophoresis, the PCR prod-
ucts were visualized using a BioImaging System (UVP
Inc.) and quantified using LabWorks Image Acquisition
and Analysis Software (UVP Inc.). Pygo2 mRNA levels
were normalized to β-actin mRNA.
Pygo2 siRNA plasmids and transfection
Three different sequences were tested for their ability to
downregulate endogenous Pygo2 expression and then
used to produce Pygo2 siRNA plasmids (GenePharma,
Shanghai, China). The different shDNA sequences were as




GGG-3′; Sequence B, 5′-GATCCCCC ACAAGTCCCTT
TCCTGGTTTCAAGAGAACCAGGAAAGGGACTTG
TGTTTT T-3′ and 5′-AGCTAAAAACACAAGTCCC
TTTCCTGGTTCTCTTGAAACCAGGA AAGGGAC
TTGTGGGG-3′; Sequence C, 5′-GATCCCCGGAGAT
CCAGTCTGTCT ACTTCAAGAGAGTAGACAGAC
TGGATCTCCTTTTT-3′ and 5′-AGCTAAAAAG GA
GATCCAGTCTGTCACTCTCTTGAAGTAGACAGAC
TGGATCTCCGGG–3′.
A549, SPC-A-1 and LTEP-a-2 cells were transfected
with the Pygo2 siRNA plasmids using Lipofectamine
2000 (Invitrogen), following the manufacturer’s instruc-
tions. The empty plasmid was used as a negative control.Transfected cells were tested for Pygo2 expression by
Western blotting and RT-PCR.
Pygo2 cDNA plasmid and transfection
We introduced cDNA plasmids encoding Mus musculus
Pygo2 (Gene ID: 68911, GenePharma, Shanghai, China)
into Pygo2 knockdown cells, which were transfected with
the Homo sapiens Pygo2 siRNA plasmids. The empty
plasmid was used as a negative control. Re-expression of
Pygo2 was confirmed by Western blot.
MTT assays
Cells were plated in 96-well tissue culture plates, allowed
to attach overnight, and then transfected. Transfected
cells were analyzed after 12 h, 24 h, 48 h or 72 h. Cell
viability was assessed by the MTT method (Sigma). To
each well, 20 μl of 5 mg/ml MTT was added, incubated
for 4 h at 37°C, then 200 μl of dimethyl sulfoxide was
added to each well and the plates were shaken for
10 min to allow the formazan crystals to dissolve. The
optical density at 490 nm was measured using a
microplate reader (Model 550, Bio-Rad, USA).
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After 48 h, transfected cells harvested from each experi-
mental group were resuspended in 50 μg/ml propidium
iodide (Sigma) and incubated for 45 min at room
temperature in the dark prior to fluorescence-activated
cell sorting analysis. The proportion of cells at each cell
cycle phase was determined using a FACS Calibur Flow
Cytometer and CellQuest 3.0 software (BD Biosciences,
San Jose, CA, USA). Experiments were performed in
triplicate.
Annexin V-FITC Apoptosis Kit (BD Pharmingen,
USA) was adopted for apoptosis detection according to
manufactory’s protocol. Briefly, cells (1 × 106) were
transfected with Pygo2 siRNA plasmids and scrambled
control, and then collected and resuspended in binding
buffer. Annexin V-FITC and propidium iodide were
added to each sample and incubated in the dark for
15 minutes before analysis by a FACS Calibur Flow
Cytometer. Data were collected and analyzed using
CellQuest 3.0 software (BD Biosciences).
Statistical analysis
All statistical calculations were performed using SPSS
11.5 for Windows software. The χ2 test was used to
examine possible correlations between Pygo2 expression
profiles and clinicopathological factors. The Kaplan–
Meier method was used to estimate the probability of
patient survival and the log-rank test was used to evaluate
differences in survival between patient subgroups. TheFigure 2 Pygo2 expression correlates negatively with patient survival
cell carcinoma or adenocarcinoma stratified by Pygo2 expression. Patients
than patients with normal Pygo2 expression (P = 0.030).study paired samples t-test was used to compare the data
from the densitometry analysis of Western blots for paired
normal lung tissues and lung cancer samples. Data from
cells in different experimental groups were compared
using the independent samples t-test. P values < 0.05 were
considered statistically significant.
Results
Nuclear localization of Pygo2 in NSCLC
To investigate the abnormalities of Pygo2 expression in
NSCLC, we analyzed Pygo2 protein subcellular localization
in 168 archived surgical tumor samples. We assessed
Pygo2 expression in a semiquantitative manner based on
the staining intensity and the percentage of tumor cells
with nuclear staining (Figure 1). Pygo2 nuclear expression
was undetectable (−) or weak (+) in normal bronchial
epithelium. Of the 168 lung cancer samples, 68.45% of
NSCLC samples had moderate (++) to strong (+++)
nuclear accumulation of Pygo2 protein (see Table 1).
These observations suggest a role of nuclear Pygo2 in
malignant epithelial cancer.
Pygo2 overexpression correlates with some NSCLC
clinicopathological factors and patient survival
We next investigated the associations between abnormal
Pygo2 expression and clinicopathological factors. We
found that abnormal Pygo2 expression occurred more
frequently in advanced tumors (P =0.019) with poor
differentiation (P = 0.015). In contrast, there were no. Kaplan–Meier curves for the analysis of 168 patients with squamous
with moderate to strong Pygo2 expression had a shorter survival time
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sion and age, sex, histological type or lymph node me-
tastasis (Table 1). In terms of survival, patients with
abnormal Pygo2 expression had a poorer overall survival
than patients with normal Pygo2 expression (P = 0.030;
Figure 2). Overall, our data show that an abnormal
Pygo2 expression profile correlates with tumor progres-
sion and poor prognosis in NSCLC.Increased Pygo2 expression in lung cancer tissues
In normal lung tissues, a major Pygo2 band was detected
at 50 kDa. In lung cancer tissues, Pygo2 staining was
significantly elevated (P = 0.007, n = 30; Figure 3A, C). In
addition, we examined the levels of Pygo2 expression in
normal and lung cancer cell lines (Figure 3B, D). Pygo2
was more highly expressed in lung cancer cell lines than
in HBE cells, moreover, the levels of Pygo2 in lung cancer
cells were similar to lung cancer tissues, as determined by
Western blot analysis. These observations suggest that
Pygo2 overexpression is a general characteristic of lung
cancer.Figure 3 Pygo2 is overexpressed in lung cancer tissues. (A) Pygo2 (50
(C1–C4) compared with the matched normal lung tissues (N1–N4). (B) Incr
compared to the immortalized bronchial epithelial cell line, HBE. Positions
were normalized to β-actin. Statistical analysis showed increased Pygo2 exp
P = 0.038; NCI-H460, P = 0.022, LTEP-a-2, P =0.042, A549, P = 0.047, BE1, P = 0siRNA-mediated Pygo2 silencing
We used siRNA to downregulate endogenous Pygo2. Of
the three sequences tested, one (sequence C) reduced
endogenous Pygo2 expression to a level that was barely
detectable by Western blotting and RT-PCR. Sequences
A and B showed a low efficiency for Pygo2 depletion
(data not shown). Following transfection with Pygo2
siRNA sequence C, A549, LTEP-a-2 and SPC-A-1 cells
displayed a reduction in endogenous Pygo2 levels. We
carried out three independent transfection experiments
from each cell line with sequence C and named them
Pygo2 siRNA1, siRNA2 and siRNA3. Reduced Pygo2 ex-
pression was confirmed by Western blotting and RT-PCR.
The empty vector was introduced into each parental cell
line and used as a negative control. We also re-introduced
Mus musculus Pygo2 cDNA plasmid to confirm that se-
quence C was specific (Figure 4).
Pygo2 knockdown inhibits lung cancer cell growth
The proliferation rate of siRNA-transfected cells was
assessed using the MTT assay (Figure 5A). We observed
a time-dependent reduction in Pygo2 expression whichkDa band) had increased signal intensity in lung cancer samples
eased Pygo2 expression was detected in different lung cancer cells
of the molecular weight markers are indicated. Pygo2 protein levels
ression in lung cancer tissues (C; P = 0.007) and cell lines (D; SPC-A-1,
.034) compared to matched normal lung tissues.
Figure 4 Pygo2 siRNA reduces Pygo2 expression. Following transfection with Pygo2 siRNAs, Pygo2 expression was analyzed by Western
blotting and RT-PCR. (A) Pygo2 protein bands were detected at approximately 50 KDa in untransfected and control SPC-A-1 cells. In contrast, cell
lines transfected with sequence C showed reduced Pygo2 expression. (B) RT-PCR analysis indicated that Pygo2 mRNA was detected as a specific
170 bp band in untransfected and control SPC-A-1 cells. After transfection with Pygo2 siRNA, expression of Pygo2 mRNA was reduced. (C) Lanes
1–3 were siRNA-transfected cells transfected with empty plasmid. Lanes 4–6 were the siRNA-transfected cells transfected with Mus musculus
Pygo2 cDNA plasmid. Protein bands representing Pygo2 at approximately 50 kDa were detected. Similar results were observed in A549 (D-F) and
LTEP-a-2 (G-I) cells.
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the lung cancer cell lines, especially at time points later
than 48 h. This data shows that Pygo2 silencing signifi-
cantly inhibited lung cancer cell proliferation.
We next analyzed the cell cycle in transfected cells at the
48 h time point by propidium iodide staining. As shown in
Figure 5B–E, Pygo2 silencing resulted in a significant in-
crease in G1-phase cells and a significant reduction in S-
phase cells, compared to untransfected cells and negative
controls. These data indicated that Pygo2 has the effect on
the regulation of the cell cycle of lung cancer cells.
In addition, the Annexin V assay was employed to
characterize the apoptotic activities of cells upon Pygo2
knockdown. Clearly, in the cells with Pygo2 knockdown,
a significant increase was observed in the population of
cells undergoing early and late apoptosis, compared with
scrambled controls (Figure 5F–I). These results suggest
that Pygo2 knockdown enhances apoptosis of the lung
cancer cells.
Discussion
Abnormal Pygo2 expression in tumor cells has been
implicated in tumor progression [2,6,9,10]. However, thepattern of Pygo2 expression in lung cancer was un-
known and the correlation of Pygo2 expression with the
clinicopathological factors of lung cancer had not been
determined. In this study, we demonstrated that Pygo2
protein levels are significantly higher in lung cancer tis-
sues than in normal lung tissues. There was a strong
correlation between Pygo2 overexpression and tumor
stage. Furthermore, Pygo2 overexpression correlated
with poor prognosis in lung cancer patients. In addition,
we revealed that siRNA-mediated Pygo2 depletion
inhibited the growth of lung cancer cells.
In the present study, we examined the subcellular
localization of endogenous Pygo2 in lung tissues by
immunohistochemical staining. We demonstrated that
Pygo2 protein was weakly detectable or undetectable in
the nuclei of normal bronchial epithelia. In contrast,
68.45% of NSCLC samples had moderate to strong
nuclear accumulation of Pygo2 proteins. To the best of
our knowledge, this is the first report of the Pygo2
expression pattern in NSCLC. Moreover, there was a
close correlation between abnormal Pygo2 expression in
lung cancer samples and some clinicopathological factors.
Abnormal Pygo2 expression was higher in tumors with a
Figure 5 Pygo2 knockdown inhibits lung cancer cell growth. (A) MTT assays showing that decreased Pygo2 expression inhibited the
proliferation of SPC-A-1, A549 and LTEP-a-2 cells. This trend was especially pronounced after 48 h. The y-axis shows the proliferation inhibition
rate (%) and the x-axis indicates time after transfection. (B) Representative flow cytometry results for SPC-A-1 cell cycle. Treatment with Pygo2
siRNA lead to a significant increase in the proportion of G-phase cells and a significant reduction in S-phase cells, compared with untransfected
and control cells. (C-E) Statistical analysis of the flow cytometry data for SPC-A-1, A549 and LTEP-a-2 cell cycles, respectively. (F-I) Apoptotic cell
death was determined by flow-cytometric analysis with Annexin V and PI staining. The percentage of apoptosis, including early and late stage of
apoptotic cell death in each group, is shown. (F) Representative results for SPC-A-1 cells showed that knockdown of Pygo2 led to an increase of
apoptotic cells compared with untransfected or control cells. (G-I) Statistical analysis of the flow cytometry data for apoptosis in SPC-A-1, A549
and LTEP-a-2 cell, respectively.
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differentiation) and correlated significantly with poor
prognosis. These observations are consistent with previ-
ous studies indicating that Pygo functions in the nu-
cleus [2,14]. Consistent with our immunohistochemical
data, Western blotting showed that Pygo2 protein levels
were increased in cancerous tissues compared with
normal lung tissues. In addition, we revealed significant
overexpression of Pygo2 in lung cancer cell lines relative
to immortal bronchial epithelial cells, which further
supports our hypothesis that Pygo2 overexpression
characterizes lung cancer malignancy.
A previous study also found that Pygo suppression re-
sults in cancer cell growth inhibition [6,10]. We therefore
reasoned that Pygo2 may regulate the proliferation of lung
cancer cell lines. We examined the proliferation rate of
A549, LTEP-a-2 and SPC-A-1 cells after siRNA-mediated
Pygo2 silencing, and showed that Pygo2 knockdown
inhibited cell proliferation, by participating in the regula-
tion of the cell cycle and apoptosis. Therefore, it is prob-
able that Pygo2 overexpression promotes malignant lung
cell growth, which may explain our findings that Pygo2
overexpression was the major defining characteristic of
NSCLC tumors and correlated with several clinicopatho-
logical factors.
How might Pygo2 influence the lung cancer cell growth?
A previous study reported that loss of Pygo2 was accom-
panied by decreased cyclin D1 and c-Myc expression, as
well as increased expression of the cell cycle inhibitor p21
[17]. Thus, Pygo2 expression is likely to be finely regulated
throughout the cell cycle. These reports suggest that
Pygo2 overexpression directly or indirectly regulates
critical cell cycle genes, thereby promoting G1–S phase
transition. However, the identity of the factors that may
participate with Pygo2 to regulate cell cycle progression in
lung cancer needs to be further explored. In addition,
stable expression of Pygo2 in HeLa cells is reported to
exert an anti-apoptotic activity by DNA fragmentation,
sub-G1 appearance, loss of mitochondrial membrane po-
tential and the activation of caspase-9 and caspase-3.
Meanwhile, Pygo2 also effectively blocks activation of the
JNK/AP-1 signaling pathway, thus maintaining the anti-
apoptotic Bcl-2 protein in an unphosphorylated state and
rendering cells resistant to vinblastine-induced apoptosis
[18]. Apoptosis is always associated with cell growth and
transformation, escaping from apoptosis susceptibility is a
method for tumor growth, and failure in the normal
apoptosis pathways contributes to tumorgenicity [19]. Our
result also showed that Pygo2 is related to apoptosis of
lung cancer cells. Pygo2 mediates cancer cell survival and
is therefore essential to the malignant tumor phenotype,
and also provides a preliminary insight into how Pygo2
overexpression leads to lung cancer. However, the precise
mechanisms need to be defined.Conclusion
Our findings show that widespread nuclear Pygo2
overexpression in NSCLC correlates with a malignant
phenotype and poor patient survival. In addition, Pygo2
contributes to the proliferation of lung cancer cells, and
regulates the apoptosis and cell cycle of lung cancer
cells, indicating that Pygo2 is required for lung cancer cell
growth. We hypothesize that increased Pygo2 protein
expression may serve as a marker of advanced NSCLC, al-
though additional work is needed to identify the specific
mechanisms of Pygo2-mediated cancer progression.
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